ArticleThe Journal of clinical investigation2000
Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice.
Article in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 103 citations in OpenAlex.
- Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside.Circulation research · 2026Review
- Dietary Ethanolamine Increases Hepatic Lipid Accumulation in Mice Fed a High-Fat Diet.The Journal of nutrition · 2026Article
- Effects of Diabetes and Hyperlipidemia in Physiological Conditions - A Review.Current diabetes reviews · 2025Review
- Methylglyoxal in Cardiometabolic Disorders: Routes Leading to Pathology Counterbalanced by Treatment Strategies.Molecules (Basel, Switzerland) · 2023Review
- Perlecan, A Multi-Functional, Cell-Instructive, Matrix-Stabilizing Proteoglycan With Roles in Tissue Development Has Relevance to Connective Tissue Repair and Regeneration.Frontiers in cell and developmental biology · 2022Review
- Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target.Metabolites · 2021Review
- Review of Alterations in Perlecan-Associated Vascular Risk Factors in Dementia.International journal of molecular sciences · 2020Review
- The Glucose Lowering Effect ofTurkish journal of pharmaceutical sciences · 2018Article
- Glycosaminoglycan remodeling during diabetes and the role of dietary factors in their modulation.World journal of diabetes · 2016Review
- Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice.Arteriosclerosis, thrombosis, and vascular biology · 2015Article
- A computational model for the analysis of lipoprotein distributions in the mouse: translating FPLC profiles to lipoprotein metabolism.PLoS computational biology · 2014Article
- Hyperglycemia impairs atherosclerosis regression in mice.The American journal of pathology · 2013Article
- The regulation of ApoB metabolism by insulin.Trends in endocrinology and metabolism: TEM · 2013Review
- Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy.Molecular vision · 2013Article
- Cardiovascular disease in children and adolescents with diabetes: where are we, and where are we going?Diabetes technology & therapeutics · 2012Review
- Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance.Hepatology (Baltimore, Md.) · 2012Article
- Role of heparanase on hepatic uptake of intestinal derived lipoprotein and fatty streak formation in mice.PloS one · 2011Article
- Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins.Hepatology (Baltimore, Md.) · 2010Article
- Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate.The Journal of biological chemistry · 2010Article
- Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice.The Journal of clinical investigation · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
We used wild-type (WT) mice and mice engineered to express either apoB-100 only (B100 mice) or apoB-48 only (B48 mice) to examine the effects of streptozotocin-induced diabetes (DM) on apoB-100- and apoB-48-containing lipoproteins. Plasma lipids increased with DM in WT mice, and fat tolerance was markedly impaired. Lipoprotein profiles showed increased levels and cholesterol enrichment of VLDL in diabetic B48 mice but not in B100 mice. C apolipoproteins, in particular apoC-I in VLDL, were increased. To investigate the basis of the increase in apoB-48 lipoproteins in streptozotocin-treated animals, we characterized several parameters of lipoprotein metabolism. Triglyceride and apoB production rates were normal, as were plasma lipase activity, VLDL glycosaminoglycan binding, and VLDL lipolysis. However, beta-VLDL clearance decreased due to decreased trapping by the liver. Whereas LRP activity was normal, livers from treated mice incorporated significantly less sulfate into heparan sulfate proteoglycans (HSPG) than did controls. Hepatoma (HepG2) cells and endothelial cells cultured in high glucose also showed decreased sulfate and glucosamine incorporation into HSPG. Western blots of livers from diabetic mice showed a decrease in the HSPG core protein, perlecan. Delayed clearance of postprandial apoB-48-containing lipoproteins in DM appears to be due to decreased hepatic perlecan HSPG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.